Markets

WaferGen Collaborates with LIH for ICELL8 Single-Cell System

WaferGen Bio-systems, Inc.WGBS recently announced a strategic alliance with public medical research center - the Luxembourg Institute of Health (LIH). Under the terms of the deal, LIH will offer laboratory services for the former's ICELL8 Single-Cell System.

This alliance will enable WaferGen Bio-systems to have access to LIH's cell culture, genomics and proteomics facilities. The agreement will further permit European researchers to assess the ICELL8 Single-Cell System. Per management, the system will be used to back LIH research programs.

The ICell8 single-cell platform can separate thousands of cells and sort out definite cells for analysis through next-generation sequencing. The whole procedure is done with the help of CellSelect automated imaging and software.

This October, WaferGen announced the commercial launch of the ICELL8 Single-Cell System at the American Society of Human Genetics annual meeting. Recently, WaferGen announced the first commercial sale of the platform to a global pharmaceutical company.

Notably, Genentech, Karolinska Institutet, The University of Texas MD Anderson Cancer Center, National Jewish Health and The Broad Institute are some of the early access partners of WaferGen's system.

We believe that the newly-penned deal with LIH will help WaferGen's ICell8 single-cell system gain better visibility in Europe. Notably in 2011, WaferGen created a fully owned subsidiary in Luxembourg to promote the company's marketing and research activities in the European market. Earlier this year, the company also set up new offices and laboratory space at the LIH.

We believe ICell8 single-cell systems' ability to identify different cell types will help researchers discover new drugs and therapeutics faster and at a lower developmental cost. This will also boost WaferGen's existing customer base.

Zacks Rank & Other Key Picks

WaferGen carries a Zacks Rank #2 (Buy).

Other well placed stocks in the same sector are Masimo MASI , Steris Plc STE and Natus Medical BABY . All the stocks sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

MASIMO CORP (MASI): Free Stock Analysis Report

NATUS MEDICAL (BABY): Free Stock Analysis Report

STERIS PLC (STE): Free Stock Analysis Report

WAFERGEN BIOSYS (WGBS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NTUS MASI STE

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More